These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 33786990)

  • 21. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
    Kelly M; O'Connor R; Townsend L; Coghlan M; Relihan E; Moriarty M; Carr B; Melanophy G; Doyle C; Bannan C; O'Riordan R; Merry C; Clarke S; Bergin C
    Br J Clin Pharmacol; 2021 Mar; 87(3):1150-1154. PubMed ID: 32687645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
    Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
    Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
    Ding J; Liu W; Guan H; Feng Y; Bao Y; Li H; Wang X; Zhou Z; Chen Z
    Medicine (Baltimore); 2021 Jul; 100(28):e26538. PubMed ID: 34260531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
    Szendrey M; Guo J; Li W; Yang T; Zhang S
    J Pharmacol Exp Ther; 2021 May; 377(2):265-272. PubMed ID: 33674391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
    Maharaj AR; Wu H; Hornik CP; Balevic SJ; Hornik CD; Smith PB; Gonzalez D; Zimmerman KO; Benjamin DK; Cohen-Wolkowiez M;
    JAMA Pediatr; 2020 Oct; 174(10):e202422. PubMed ID: 32501511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.
    Badary OA
    Pharmacogenomics J; 2021 Jun; 21(3):275-284. PubMed ID: 33542445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series.
    Lepage MA; Rozza N; Kremer R; Grunbaum A
    Clin Toxicol (Phila); 2021 Jul; 59(7):644-647. PubMed ID: 33641562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Data mining methodology for response to hypertension symptomology-application to COVID-19-related pharmacovigilance.
    Xu X; Kawakami J; Millagaha Gedara NI; Riviere JE; Meyer E; Wyckoff GJ; Jaberi-Douraki M
    Elife; 2021 Nov; 10():. PubMed ID: 34812146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.
    Baburaj G; Thomas L; Rao M
    Arch Med Res; 2021 Apr; 52(3):261-269. PubMed ID: 33257051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.
    Luo M; Wu B; Li Y; Wu F
    Int J Clin Pharm; 2022 Oct; 44(5):1179-1187. PubMed ID: 35857159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Geographic Variation in Antidiabetic Agent Adherence and Glycemic Control Among Patients with Type 2 Diabetes.
    Tan E; Yang W; Pang B; Dai M; Loh FE; Hogan P
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1195-202. PubMed ID: 26679968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 and the burning issue of drug interaction: never forget the ECG.
    Sciaccaluga C; Cameli M; Menci D; Mandoli GE; Sisti N; Cameli P; Franchi F; Mondillo S; Valente S
    Postgrad Med J; 2021 Mar; 97(1145):180-184. PubMed ID: 32820084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brief review on repurposed drugs and vaccines for possible treatment of COVID-19.
    De P; Chakraborty I; Karna B; Mazumder N
    Eur J Pharmacol; 2021 May; 898():173977. PubMed ID: 33639193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
    Saleh M; Gabriels J; Chang D; Fishbein J; Qiu M; Mountantonakis SE; Epstein LM;
    Circ Arrhythm Electrophysiol; 2020 Nov; 13(11):e008937. PubMed ID: 33003964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.